Analysts Offer Predictions for MIRM FY2025 Earnings

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) – Stock analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for Mirum Pharmaceuticals in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst J. Schimmer forecasts that the company will post earnings of ($1.55) per share for the year. The consensus estimate for Mirum Pharmaceuticals’ current full-year earnings is ($1.45) per share.

A number of other equities research analysts have also recently weighed in on MIRM. Citigroup lifted their price objective on shares of Mirum Pharmaceuticals from $65.00 to $68.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Robert W. Baird upped their price objective on Mirum Pharmaceuticals from $44.00 to $50.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. Leerink Partners lifted their target price on Mirum Pharmaceuticals from $47.00 to $49.00 and gave the stock an “outperform” rating in a report on Thursday, October 17th. Finally, HC Wainwright reissued a “buy” rating and issued a $66.00 price target on shares of Mirum Pharmaceuticals in a report on Wednesday, November 13th. Ten equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $57.10.

Mirum Pharmaceuticals Stock Performance

Shares of MIRM opened at $47.53 on Thursday. The firm has a fifty day moving average of $43.70 and a 200-day moving average of $41.45. Mirum Pharmaceuticals has a 1 year low of $23.14 and a 1 year high of $49.27. The company has a market cap of $2.28 billion, a price-to-earnings ratio of -23.53 and a beta of 0.98. The company has a debt-to-equity ratio of 1.33, a quick ratio of 3.15 and a current ratio of 3.34.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.15. The business had revenue of $90.38 million during the quarter, compared to analyst estimates of $81.99 million. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. The company’s quarterly revenue was up 89.4% on a year-over-year basis. During the same period in the previous year, the business posted ($0.57) EPS.

Hedge Funds Weigh In On Mirum Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the stock. Golden State Equity Partners raised its holdings in shares of Mirum Pharmaceuticals by 1,390.8% during the fourth quarter. Golden State Equity Partners now owns 19,380 shares of the company’s stock worth $801,000 after acquiring an additional 18,080 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its position in Mirum Pharmaceuticals by 10.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,179 shares of the company’s stock worth $421,000 after purchasing an additional 1,003 shares during the last quarter. R Squared Ltd purchased a new stake in shares of Mirum Pharmaceuticals during the 4th quarter worth about $69,000. Secure Asset Management LLC lifted its holdings in shares of Mirum Pharmaceuticals by 9.3% during the 4th quarter. Secure Asset Management LLC now owns 39,920 shares of the company’s stock valued at $1,651,000 after buying an additional 3,406 shares during the last quarter. Finally, Avanza Fonder AB bought a new stake in shares of Mirum Pharmaceuticals in the 4th quarter valued at approximately $189,000.

Insider Activity at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, insider Joanne Quan sold 6,969 shares of Mirum Pharmaceuticals stock in a transaction dated Friday, January 17th. The stock was sold at an average price of $45.86, for a total transaction of $319,598.34. Following the transaction, the insider now owns 5,649 shares of the company’s stock, valued at $259,063.14. The trade was a 55.23 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Christopher Peetz sold 7,489 shares of the stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $42.82, for a total transaction of $320,678.98. Following the completion of the sale, the chief executive officer now directly owns 119,359 shares of the company’s stock, valued at $5,110,952.38. This trade represents a 5.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 19,706 shares of company stock valued at $875,697. Company insiders own 22.87% of the company’s stock.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.